Haleon plc (NYSE:HLN) Shares Sold by JTC Employer Solutions Trustee Ltd

JTC Employer Solutions Trustee Ltd lessened its stake in shares of Haleon plc (NYSE:HLN) by 64.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 38,569 shares of the company’s stock after selling 69,580 shares during the period. JTC Employer Solutions Trustee Ltd’s holdings in Haleon were worth $367,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of HLN. FMR LLC lifted its position in shares of Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares during the last quarter. Sculptor Capital LP lifted its holdings in shares of Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after purchasing an additional 3,592,000 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Haleon by 8.6% in the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Down 0.9 %

HLN traded down $0.08 during trading on Monday, reaching $9.02. 3,539,394 shares of the stock traded hands, compared to its average volume of 7,724,963. The stock has a market cap of $40.83 billion, a price-to-earnings ratio of 26.53, a price-to-earnings-growth ratio of 2.95 and a beta of 0.29. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The stock’s 50-day simple moving average is $9.59 and its two-hundred day simple moving average is $9.69.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of research analyst reports. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday. UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Finally, Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.